Momenta Sues Viatris Over Copaxone Generic – Five Years After Launch
Viatris’ Partner Natco: ‘This Is A Meritless Suit’
Executive Summary
One Copaxone (glatiramer acetate) ANDA sponsor is suing another for alleged patent infringement, with Momenta filing a lawsuit against Viatris and its partners in a US district court.
You may also be interested in...
Viatris’ Once-Monthly Copaxone Filing Imminent, Botox ‘On Track’
Fresh from offloading almost all its interests in biosimilars to Biocon, Viatris continues to develop several follow-on products, which it hopes will add $1bn to the company’s top line by the end of the decade.
Viatris Keeping Powder Dry On Symbicort With Key Ruling Imminent
In the coming days, Viatris expects to hear back from a court in West Virginia over its legal tussle with AstraZeneca on Symbicort IP. The US-based player has intimated that it may launch the product dependent on the court’s verdict.
Nexavar Rival Offers Natco Opportunity To Build On Lenalidomide Launch
Viatris and Natco have introduced the first US generic version of Nexavar, with the exclusive launch expected to further boost India’s Natco after a healthy financial fourth quarter that was bolstered by revenues from the firm’s recent launch of a Revlimid rival with Teva.